Silo Pharma confirms compliance with Nasdaq's bid price requirements and focuses on advancing its drug development programs.
Quiver AI Summary
Silo Pharma announced that it has regained compliance with Nasdaq's minimum closing bid price requirement, allowing its common stock to continue trading on the Nasdaq Capital Market. This confirmation was received as of June 17, 2026. CEO Eric Weisblum expressed gratitude for investor support and reaffirmed the company’s commitment to long-term value creation as it moves toward a first-in-human clinical trial of its lead drug, SPC-15, aimed at treating PTSD. Silo Pharma focuses on innovative therapeutics for conditions such as PTSD, chronic pain, and Alzheimer's disease, collaborating with universities and laboratories for its research.
Potential Positives
- Silo Pharma has regained compliance with Nasdaq's minimum closing bid price requirement, allowing its common stock to continue trading on the Nasdaq Capital Market.
- The company expresses confidence in its progress toward first-in-human clinical trials for its lead drug targeting PTSD, suggesting future growth potential.
- Silo's diverse portfolio includes innovative therapeutics addressing significant unmet medical needs such as PTSD, fibromyalgia, and Alzheimer's disease, highlighting its research-focused strategy.
Potential Negatives
- The announcement of regaining compliance with Nasdaq's minimum bid requirement suggests that the company's stock faced previous challenges, potentially indicating market volatility or lack of investor confidence.
- The use of "forward-looking statements" indicates uncertainty in the company's future performance, which may concern investors about the risk involved in their investments.
- As a developmental-stage company, Silo Pharma's reliance on future clinical trials (such as SPC-15 for PTSD) entails inherent risks and challenges that may impede its progress and affect stockholder value.
FAQ
What announcement did Silo Pharma make on June 18, 2026?
Silo Pharma announced it has regained compliance with Nasdaq’s minimum closing bid price requirement.
What does Silo Pharma specialize in?
Silo Pharma focuses on developmental-stage biopharmaceuticals and novel therapeutics targeting underserved conditions.
What is Silo Pharma's lead drug targeting?
The lead drug, SPC-15, targets post-traumatic stress disorder (PTSD).
How does Silo Pharma conduct its research?
Silo Pharma conducts research in collaboration with leading universities and laboratories.
Who is the CEO of Silo Pharma?
Eric Weisblum is the Chief Executive Officer of Silo Pharma.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Hedge Fund Activity
We have seen 9 institutional investors add shares of $SILO stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANSON FUNDS MANAGEMENT LP removed 952,381 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $323,809
- DRW SECURITIES, LLC removed 333,733 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $120,043
- GEODE CAPITAL MANAGEMENT, LLC added 87,126 shares (+93.8%) to their portfolio in Q1 2026, for an estimated $31,339
- ADVISORSHARES INVESTMENTS LLC added 64,458 shares (+10.8%) to their portfolio in Q1 2026, for an estimated $23,185
- XTX TOPCO LTD removed 39,816 shares (-70.0%) from their portfolio in Q1 2026, for an estimated $14,321
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 33,218 shares (+112.3%) to their portfolio in Q1 2026, for an estimated $11,948
- CITADEL ADVISORS LLC added 21,448 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,714
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo’s common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.
“We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders. Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories.
silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
[email protected]
